Based on the long-term experiences with haplo-HSCT according to the Beijing Protocol, Lu, Huang, and colleagues proposed that graft-versus-host disease (GVHD) and rejection after haplo-HSCT could be prevented by the co-infusion of G-CSF-mobilized BM and PB and the administration of anti-thymocyte globulin [27, 28]. This evidence concerns the gene CSF3 and graft versus host disease.